Back to top
more

Selecta Biosciences, Inc. (SELB)

(Delayed Data from NSDQ)

$2.35 USD

2.35
240,236

+0.23 (10.85%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.36 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CHMP Endorses BioMarin's (BMRN) Voxzogo for Use in Infants

by Zacks Equity Research

A final decision study on BioMarin's (BMRN) Voxzogo to treat children above four months with achondroplasia is expected before year's end.

CHMP Endorses AstraZeneca's (AZN) Enhertu in Lung Cancer

by Zacks Equity Research

Data from a mid-stage study shows that treatment with AstraZeneca's (AZN) Enhertu achieved strong and durable tumor responses in certain non-small cell lung cancer patients.

Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 22.22% and 46.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Aeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 40.23% and 104.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -37.50% and 59.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 25% and 32.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -200% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 8.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Elevance Health's (ELV) Low-Cost MA Plans to Widen U.S. Base

by Zacks Equity Research

Elevance Health (ELV) devises suitable Medicare Advantage plans containing supplemental benefits, which consumers can avail in the 2023 Annual Enrollment Period.

Selecta Biosciences, Inc. (SELB) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 300% and 83.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vertex (VRTX) to Buy ViaCyte to Speed Up VX-880 Program

by Zacks Equity Research

Vertex (VRTX) will acquire ViaCyte for $320 million in cash.

BioMarin (BMRN) Stock Jumps 5.4%: Will It Continue to Soar?

by Zacks Equity Research

BioMarin (BMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 22.22% and 80.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 42.86% and 49.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Amryt Pharma PLC Sponsored ADR (AMYT) Tops Q4 Earnings Estimates

by Zacks Equity Research

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 207.14% and 3.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Horizon (HZNP) Submits sBLA for Krystexxa Label Expansion

by Zacks Equity Research

Horizon (HZNP) files a supplemental biologics license application to the FDA for Krystexxa plus methotrexate to treat people living with uncontrolled gout.

Selecta (SELB) Down on FDA's Clinical Hold on Phase I/II Study

by Zacks Equity Research

The FDA issues a clinical hold on Selecta's (SELB) phase I/II study evaluating SEL-302 for the treatment of patients with methylmalonic acidemia. Shares down in after-hours trading.

Selecta Biosciences, Inc. (SELB) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -128.57% and 82.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 55.56% and 81.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for July 14th

by Zacks Equity Research

COHU, NTRB, HELE, CNR, and SELB have been added to the Zacks Rank #5 (Strong Sell) List on July 14, 2021

Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -83.33% and 60.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 6.67% and 105.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.